About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, February 25th, 2015

The QualityStocks
Daily Stock List

graphic
graphic

InsPro Technologies Corp. (ITCC)

StockMister, Penny Stock Circle, 1-2-3 Stock Alerts, StockMarketQuote.us, DrStockPick, and Pumps and Dumps reported on InsPro Technologies Corp. (ITCC), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

InsPro Technologies Corp., by way of its subsidiary, InsPro Technologies, LLC, offers InsPro Enterprise. This is an end-to-end, web-based policy administration system used by insurance carriers and third-party administrators. Eddystone, Pennsylvania-headquartered InsPro is a leading provider of Life and Health core policy administration software that allows insurance carriers and third-party administrators to quickly respond to evolving market needs, improve customer service, and reduce operating costs. InsPro Technologies’ shares trade on the OTC Markets Group’s OTCQB.

The InsPro Enterprise design provides carriers the option to install the solution as an end-to-end straight through processing suite or on a modular, componentized basis to address immediate areas of concern. The InsPro Enterprise suite includes Product Configuration Workbench, New Business and Underwriting, Billing and Collections, Policy Administration, Agent Management and Commissions, Claims, Document Management, Web Portals, and Data Analytics components.

The Company offers its solutions through standard software licensing, as a hosted solution, or through Software as a Service (SaaS) delivery. Customers can manage the entire product and policy lifecycle on a single integrated platform. InsPro Enterprise is a single technology solution used to manage all insurance processing requirements supporting multiple product lines and hybrid products for group and individual policies on a single web-based platform.

This past November, InsPro Technologies announced its financial results for the quarter ended September 30, 2014. Concerning Revenues, they were $5,973,754 in Q3 2014. This represents a 109 percent increase versus the $2,856,841 in Q3 2013. This increase in revenue was because of an increase of $1,460,459 in professional services from a number of ongoing implementations, a $1,300,000 license for an InsPro Enterprise™ upgrade, and an increase in ASP/hosting and maintenance revenues resulting from client growth.

Revenues were $13,818,010 in the first nine months of 2014 versus $11,746,419 in the first nine months of 2013. Revenue growth in the first nine months of 2014 was because of a $2,496,725 increase in professional services, higher ASP/hosting revenue of $579,073, and $166,598 of higher maintenance revenue. These were all the result of increased fees from established and recent implementations of InsPro Enterprise™.

InsPro Technologies Corp. (ITCC), closed Wednesday's trading session at $0.073, down 3.95%, on 20,778 volume with 4 trades. The average volume for the last 60 days is 39,855 and the stock's 52-week low/high is $0.022/$0.49.

ULURU, Inc. (ULUR)

Zacks, TopPennyStockMovers, BabyBulls, and SmallCapVoice reported earlier on ULURU, Inc. (ULUR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ULURU, Inc. is a specialty pharmaceutical company with corporate headquarters in Addison, Texas. The Company is focusing on the development of a portfolio of wound management and oral care products. This is to provide patients and consumers improved clinical outcomes through controlled delivery using the Company’s innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. ULURU lists on the OTC Markets’ OTCQB.

The Company’s business strategy is to develop and commercialize a customer focused portfolio of innovative wound care products to treat the different phases of wound healing. In addition, ULURU’s strategy involves developing the oral-transmucosal technology and generating revenues through many licensing agreements.

ULURU’s products include Altrazeal®. It developed and commercializes Altrazeal® - a transforming powder dressing with proprietary Nanoflex® technology, for the management of exuding wounds. Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds. These include diabetic foot ulcers, venous leg ulcers, as well as geriatric wounds.
 
ULURU’s products also include Aphthasol®. It contains 5% amlexanox in an adhesive oral paste. Aphthasol® is Food and Drug Administration (FDA) approved and indicated for the treatment of aphthous ulcers in people with normal immune systems.

ULURU also has its OraDisc™A. It developed OraDisc™ A, a novel mucoadhesive, water-erodible disc incorporating 2mg of amlexanox, for the treatment and prevention of aphthous ulcers. Its OraDisc™ B is a mucoadhesive erodible disc containing 15 mg of benzocaine, which has undergone development for the treatment of oral pain.

ULURU also developed a unique, patented delivery strip for whitening teeth which completely erodes (OraDisc™ W- Erodible Whitening Strip for Teeth). Its proprietary tooth whitening product consists of a laminated bilayer strip that utilizes the OraDisc™ technology.

Last month, ULURU provided an update on recent developments. Initial shipments, which will be reflected in Q4 results, were made for Germany and Saudi Arabia. Altrazeal® has now been launched onto the German market with the sales force completing extensive training on January 6, 2015. Recently, ULURU was advised by the Chinese patent office that the patent covering Altrazeal® has been issued. This further expands the extensive global patent protection ULURU has attained for Altrazeal®.

ULURU, Inc. (ULUR), closed Wednesday's trading session at $0.825, up 17.86%, on 37,018 volume with 22 trades. The average volume for the last 60 days is 18,722 and the stock's 52-week low/high is $0.6721/$1.83.

Applied Minerals, Inc. (AMNL)

Real Pennies reported previously on Applied Minerals, Inc. (AMNL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Applied Minerals, Inc., through its ownership of the historic Dragon Mine deposit, is the leading international source of Halloysite Clay and related technology solutions. The Company markets its products under the Dragonite™ trade name. It is the leading producer of Halloysite clay and advanced natural iron oxide solutions from its wholly-owned Dragon Mine property in Utah. Applied Minerals is headquartered in New York, New York.

The Company’s products address the global need for high performance, eco-friendly solutions for a variety of industrial applications. Halloysite is an aluminosilicate clay. It exhibits a rare, naturally occurring hollow tubular structure. Halloysite tubes have a length in the range of 0.5 - 3.0 microns, an exterior diameter in the range of 50 - 70 nanometers, and an internal diameter (lumen) in the range of 15 - 30 nanometers.

Applied Minerals serves the traditional halloysite markets for use in technical ceramics and catalytic applications. Additionally, it has developed niche applications that benefit from the tubular morphology of its halloysite. These applications include carriers of active ingredients in paints, coatings and building materials, environmental remediation, agricultural applications and high-performance additives & fillers for plastic composites.

Applied Minerals’ Dragonite™ is a versatile Halloysite product grade. It has a broad assortment of applications. Its Dragonite-XR™ product grade offers unique advantages versus other reinforcing fillers, including glass fiber, mica, wollastonite or talc. It is an advanced reinforcing filler.

The Company’s Dragonite-HP™ is a high performance additive for engineering thermoplastics used at loadings of only 1-3 percent. It offers first-rate mechanical performance and cycle time reduction. In addition, Applied Minerals’ Dragonite-PureWhite™ is the highest purity Dragonite™ product. It meets the strict specifications of the cosmetic industry. Pertaining to Iron Oxide products, Applied Minerals offers AMIRON™. This is an advanced natural iron oxide for an array of pigmentary and technical applications.

Applied Minerals announced in May 2014 that it signed a non-binding Letter of Intent (LOI) to form an agreement with The Lorama Group, Inc. to market, sell, and distribute its AMIRON™ line of iron oxide-based pigments worldwide to the paint and coatings industry on an exclusive basis. Lorama is the leading global supplier of paint emulsion technologies and products. It supplies the world's leading paint and coatings companies.

Applied Minerals, Inc. (AMNL), closed Wednesday's trading session at $0.6499, down 0.02%, on 27,800 volume with 8 trades. The average volume for the last 60 days is 38,377 and the stock's 52-week low/high is $0.495/$0.95.

Arch Therapeutics, Inc. (ARTH)

Wall Street Resources and RedChip reported on Arch Therapeutics, Inc. (ARTH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Arch Therapeutics, Inc. is a medical device company that lists on the OTC Bulletin Board. It is developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s aim is to develop and commercialize products based on its pioneering technology platform, which makes surgery and interventional care faster and safer for patients. Arch Therapeutics has its corporate head office in Wellesley, Massachusetts.

The underlying technology, exclusively licensed from a leading university, supports an imaginative platform of smart materials that fulfill the criteria as a solution for a specialized field the Company calls, “stasis and barrier applications.” Arch Therapeutics’ flagship development stage product candidate is known as AC5™ (AC5 Surgical Hemostatic Device™). This is a synthetic peptide consisting of naturally occurring amino acids.

AC5™ is undergoing design to sophisticatedly achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures. Its solution smartly controls the movement of fluids and substances. AC5™ stops bleeding fast. AC5™ conforms to irregular wound geometry and assists in maintaining a clear field of vision directly into the wound area.

AC5™, when squirted or sprayed onto a wound, rapidly intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. That structure provides a barrier to leaking substances (including blood and other bodily fluids) regardless of kind of surgery or, based on early data, clotting ability, and healing occurs normally.

The Company indicates that in preclinical tests, AC5™ has been simple, effective, and versatile. So far, biocompatibility has been excellent and healing of tissue treated with the device has been normal.

This week, Arch Therapeutics reported that it obtained favorable data from an independent third party pilot animal study, which compared the hemostatic activity of AC5 Surgical Hemostatic Device with a commonly used and commercially available flowable gelatin (gelatin) hemostatic agent.

Mr. Terrence W. Norchi, MD, President and Chief Executive Officer of Arch Therapeutics, said, "This study presents another important performance data point that highlights the potential of AC5. Data to date have shown that AC5 can stop bleeding rapidly, and this study provided further evidence that AC5 may have superior qualities when compared to a successful and commonly used hemostatic agent. We highly anticipate the outcomes of further studies, and we remain excited about the prospects of AC5 and our product platform as we advance the portfolio through a methodical development plan."

Arch Therapeutics, Inc. (ARTH), closed Wednesday's trading session at $0.2075, down 4.82%, on 140,678 volume with 37 trades. The average volume for the last 60 days is 148,927 and the stock's 52-week low/high is $0.15/$0.454.

Peak Pharmaceuticals, Inc. (PKPH)

Today we are reporting on Peak Pharmaceuticals, Inc. (PKPH), here at the QualityStocks Daily Newsletter.

Peak Pharmaceuticals, Inc. engages in the research, development, sales and marketing of safe, hemp-based, medicinal products and supplements. The Company specializes in pharmaceutical-grade, hemp-based nutraceutical and supplement products for the human and animal health markets. Its goal is to become a worldwide leader in the research, development, sales and marketing of medicinal hemp and cannabinoid products. OTCQB-listed, Peak Pharmaceuticals is based in Boulder County, Colorado.

The Company acquired an exclusive worldwide license and rights to the products and technologies developed by Canna-Pet LLC in late-2014 in exchange for royalties. Peak Pharmaceuticals’ goal is to implement strict biotechnological and pharmaceutical standards in its R&D, operations, and manufacturing, to attain the gold standard for hemp-based, CBD-containing products.

The Company is first concentrating on expanding its presence in the veterinary market. It is working to launch new products and target global veterinary health markets. Along with this activity, it aims to develop new, proprietary hemp cultivars and hemp products for the human health markets, taking advantage of formulation and manufacturing experience gained from the Canna-Pet™ products, and in-house experience with drug discovery and development.

Canna-Pet™ products for pet health are safe and legal. They are also non-GMO Hemp, made in the United States of America, and veterinarian recommended. The Company offers Canna-Pet™ products as capsules in four dosages, and as Canna-Biscuits™ treats.

Peak Pharmaceuticals’ intention is to develop enhanced and proprietary hemp extraction technologies and cultivars, and build a portfolio of intellectual property (IP). It will accomplish this through strategic collaborations with universities, clinicians, as well as research institutions.

Last week, Peak Pharmaceuticals announced results of operations for the three months ending December 31, 2014. This includes revenue of $161,360 and gross profit of $117,338 or 72.7 percent. All revenues were earned because of its exclusive, worldwide license to the Canna-Pet™ veterinary products and brand.

The product sales were through its online e-commerce website and select retailers. Royalty payments under the license were $25,615 for the three month period ended December 31, 2014. At December 31, 2014, cash on hand was $281,984.

Peak Pharmaceuticals, Inc. (PKPH), closed Wednesday's trading session at $0.35, down 2.78%, on 169,528 volume with 50 trades. The average volume for the last 60 days is 19,732 and the stock's 52-week low/high is $0.1001/$3.3333.

Stevia First Corp. (STVF)

Wall Street Resources, Investor Relations, PennyStocks24, Stock Roach, StockHideout, 007 Stock Chat, PennyStockSpy, Stock Gumshoe, TopStockAnalysts, ProfitableTrading, and SmallCapVoice reported on Stevia First Corp. (STVF), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

Stevia First Corp. is an agricultural biotechnology company based in California's Central Valley growing region. The Company is centering on the industrial scale production of stevia. Stevia is an all-natural zero-calorie sweetener. Stevia First develops proprietary fermentation technologies for production of stevia, an alternative sweetener. The OTCQB-listed Company has its headquarters in Yuba City, California.

Stevia First is working to establish a vertically-integrated enterprise in the United States that uses technological expertise in fermentation-based stevia production and improves upon traditional stevia farming and processing methods. The Company launched in 2011 with a purpose to provide a healthy mainstream solution for the twin diabetes and obesity epidemics.

Stevia is a plant from the sunflower family that is native to Paraguay.  The leaf of the stevia plant has 9 to 12 sweet-tasting compounds called steviol glycosides. This includes Stevioside (STV) and Rebaudioside A, the sweetest and best tasting of the compounds. Very high purity (95 percent or higher) extracted from the stevia leaf is known as Reb A. This is used in powder or liquid form to increase the intensity of sweeteners in a food, beverage, or tabletop sweetener and/or to improve taste.

Today, Stevia First advised that the results from the 2014 growing season include major advancements in the area of herbicide use in Stevia leaf production and continued momentum towards increasing U.S. production. During the 2014 growing season, Stevia First supported the USDA IR-4 program implementing Stevia crop safety trials located at a number of sites, which included an array of important herbicides typically used in the Western U.S. These trials are vitally important to increasing North American Stevia leaf production based on conventional practices.

Mr. Robert Brooke, Stevia First Chief Executive Officer, said, "We continue to lay the groundwork and build relationships to enable a truly modern supply chain for this lucrative product. We are thrilled to partner with growers and organizations that also share our vision that includes significant North American production."

Stevia First Corp. (STVF), closed Wednesday's trading session at $0.355, up 1.43%, on 428,594 volume with 146 trades. The average volume for the last 60 days is 156,308 and the stock's 52-week low/high is $0.2901/$0.5199.

Enumeral Biomedical Holdings, Inc. (ENUM)

Today we are reporting on Enumeral Biomedical Holdings, Inc. (ENUM), here at the QualityStocks Daily Newsletter.

Enumeral Biomedical Holdings, Inc. is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. The Company is building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and taking advantage of the breadth of its technology via strategic collaborations. Its innovative platform enables it to identify and characterize promising new drugs relevant to cancer, infectious and inflammatory diseases.

Enumeral Biomedical Holdings’ corporate offices and research and development operations are in Cambridge, Massachusetts. First incorporated in 2009, the Company commenced operations in 2011. Subsequently, Enumeral Biomedical Holdings was incorporated in Delaware in 2014. The Company began trading on August 4, 2014.

Enumeral Biomedical Holdings’ immunoprofiling platform harnesses The Power of Human™. The Company believes that its cellular functional profiling techniques provide for a deeper understanding of the diversity of human responses and provide a more rational foundation to guide immunotherapy design and development.

The Company’s belief is that it has a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation. It believes its unique capabilities enable it to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient.

The core technology behind Enumeral’s platform was developed at, and licensed from, the Massachusetts Institute of Technology, Harvard University, and Whitehead Institute for Biomedical Research and Massachusetts General Hospital. The Company is enabling and hastening the discovery and development of novel antibody immunotherapies, or immunomodulators, which are validated with its human-driven immune profiling platform.

On January 12, 2015, Enumeral announced that it signed an agreement with Memorial Sloan Kettering Cancer Center. The agreement is part of Enumeral’s Phase II Small Business Innovation Research (SBIR) grant with the National Cancer Institute. The agreement will deploy the Company’s human tissue immune-oncology profiling technology at MSK in the laboratory of Jedd D. Wolchok, MD, PhD.  Dr. Wolchok is the Chief of Melanoma and Immunotherapeutics in the Clinical Investigation Department.

This week, Enumeral Biomedical Holdings announced that it appointed Mr. Paul J. Sekhri to its Board of Directors. Mr. Sekhri is an accomplished industry executive. He has over 25 years of experience in life sciences strategy, corporate development, and corporate finance. Mr. Sekhri has served in senior leadership positions at a number of pharmaceutical companies, including Novartis, Teva, and Sanofi. He is presently President and CEO of Lycera, and he also serves on its Board of Directors.

Enumeral Biomedical Holdings, Inc. (ENUM), closed Wednesday's trading session at $0.8005, down 7.82%, on 6,224 volume with 4 trades. The average volume for the last 60 days is 32,417 and the stock's 52-week low/high is $0.0216/$2.25.

GulfSlope Energy, Inc. (GSPE)

Today we choose to report on GulfSlope Energy, Inc. (GSPE), here at the QualityStocks Daily Newsletter.

GulfSlope Energy, Inc. is an independent oil and natural gas company that lists on the OTC Market Group’s OTCQB. The Company concentrates on exploring offshore U.S. Gulf of Mexico. Its team has a track-record of discovering and developing multi-billion dollar projects globally with greater than 300 years of combined experience in the oil and gas exploration industry. GulfSlope Energy has its corporate head office in Houston, Texas.

GulfSlope uses 2.2 million acres of 3D seismic data to identify high quality exploration prospects. These data incorporate advanced processing technologies. These include beam and Reverse Time Migration (RTM) imaging. The Company integrates its wide-ranging 3D seismic and geological databases. Therefore, GulfSlope can identify leasing opportunities it believes have convincing characteristics regarding size, geological attributes and potential for economic returns.

Concerning its oil & natural gas exposure, GulfSlope Energy has 2 billion boe of net conventional recoverable resources. The Company has 21 blocks with 17 prospects ranging from 30-280 MMboe. Furthermore, regarding the 17 prospects, the average size is 120 MMboe. It has an independent 3rd party evaluation of prospect sizes. DeGolyer and MacNaughton reviewed GulfSlope Energy’s 17 individual prospects. The 17 prospects are consistent with deepwater Miocene evaluations discovered by major oil companies.

Pertaining to its Drilling Program, GulfSlope Energy has multiple exploration wells planned by the end of 2016. It is presently focusing on pre-drill operations. The Company has a hybrid operating model with a preference to operate. GulfSlope has a specialized technical team with extensive Gulf of Mexico success. The Gulf of Mexico has some of the lowest breakeven costs in the E&P industry today.

Concerning its Phase 1 Drilling Program, GulfSlope Energy has high-graded five prospects with mean unrisked resource potential of 623 MMboe. The focus of the Company’s operations in 2015 include pre-drilling operations started for Phase 1 prospects and preparing to drill as operator; this may change with partnering. GulfSlope is looking to capitalize on strategic advantages provided by exploration work to identify undervalued producing assets.

GulfSlope Energy, Inc. (GSPE), closed Wednesday's trading session at $0.17, up 28.30%, on 720,499 volume with 30 trades. The average volume for the last 60 days is 185,511 and the stock's 52-week low/high is $0.065/$4.95.

graphic

The QualityStocks
Company Corner

graphic
graphic

Boreal Water Collection, Inc. (BRWC)

The QualityStocks Daily Newsletter would like to spotlight Boreal Water Collection, Inc. (BRWC). Today, Boreal Water Collection, Inc. closed trading at $0.0021, up 5.00%, on 1,060,000 volume with 6 trades. The stock’s average daily volume over the past 60 days is 820,888, and its 52-week low/high is $0.002/$0.03.

Boreal Water Collection, Inc. today issued a letter to Shareholders from the Company's Chief Executive Officer, Francine Lavoie, covering advancements of Boreal Water's mission to provide high-end private labeled bottled water, including how last year the company was very successful at gaining multiple prestigious and high-end accounts. Notably, in 2014 the company's baby water product line successfully entered the Chinese market and is now in many high-end retail outlets and online retailers. BRWC's baby water is recognized in China as being pure, sodium free, BPA free, and bromate free with low mineral content and a balanced PH, making it the perfect high-quality water for babies to drink.

Boreal Water Collection, Inc. (BRWC) is an established water bottler of premium private-labeled bottled water products tailored for each client’s particular need, be it publicity, promotion, marketing, internal use or a specific event. This emphasis on customization and quality has earned Boreal an impressive reputation, evidenced by its prestigious customer base of high-end beverage brands, retailer channels, high-end hotels and restaurant chains such as H&M, Mercedes, W Hotels, Dean & Deluca, Fred Water, Wat-aah, Saks Fifth Ave, Balance Water, NY Quin Hotel, Bouchon Bakery and Princeton University, just to name a few!

Located 90 miles north New York City, Boreal’s plant is only 17 miles from its well-protected source of natural spring water, a pristine and abundant spring source deep inside the heart of the Catskill Mountains. The spring’s exceptional geological and geographical features have created the perfect environment for Boreal’s low-mineral, sodium-free and well-balanced PH water. With exclusive exploitation rights, Boreal has a confirmed volume in excess of thousands of millions of gallons.

Boreal offers a line of award-winning water products, including functional enhanced water, infused water, carbonated water, vitamins enhanced water, flavored still or sparkling, minerals enhanced water, oxygenated water, electrolyte water, distilled water, alkaline water, caffeinated water and natural spring water.

Accommodating this plentiful water supply and range of product offerings, Boreal has established a 75,000-square foot manufacturing facility. Boreal can process a full range of water and bottle types and has the most creative staff for all private labeling needs. The company offers fully integrated turnkey service, made-to-order labeling along with distinctive water bottles. In short, Boreal is a “Boutique Bottler” and is focusing on becoming the leader of this attractive niche of the growing multi-billion dollar bottled water industry. Disclaimer

Boreal Water Collection, Inc. Company Blog

Boreal Water Collection, Inc. News:

Boreal Water Collection Releases Open Letter to Shareholders

Boreal Water Collection to Exhibit at China's Largest Food Show

Boreal Water Collection Reports Continued Growth in the Third Quarter of 2014, Sales Increase by 14% While Profitability Rises by 57%

Cleartronic, Inc. (CLRI)

The QualityStocks Daily Newsletter would like to spotlight Cleartronic, Inc. (CLRI). Today, Cleartronic, Inc. closed trading at $0.105, even for the day, on 460 volume with 1 trade. The stock’s average daily volume over the past 60 days is 928, and its 52-week low/high is $0.04/$0.5499.

Cleartronic, Inc. announced today that it has entered into a new License Agreement with Collabria LLC, a communications software company based in Tampa, Florida. The agreement strengthens the relationship between the companies and names Cleartronic, together with its newly formed subsidiary ReadyOp Communications, Inc., as the primary conduit for future marketing and sales of the ReadyOp platform developed and currently being marketed by Collabria LLC.

Cleartronic, Inc. (CLRI) is a technology holding company that creates and acquires operating subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises.

VoiceInterop, Inc., a wholly owned subsidiary, is a provider of patented IP communication gateways and communication software. Its gateways are marketed worldwide direct to customers as well as through a network of value added resellers. VoiceInterop has also developed an interoperable communication solution for use by airports. The company markets, installs and supports this interoperability solution directly to airports. International airports currently using the VoiceInterop communication solution include Dulles, Reagan, Omaha, Cincinnati, Green Bay and West Palm Beach.

A recent license agreement provides Cleartronic with the right to market Collabria LLC’s revolutionary ReadyOp™ command, control and communication platform. ReadyOp is a web-based application that integrates multiple databases and a robust communications platform supporting day-to-day activities for planning and managing small- and large-scale events. ReadyOp is designed for fast, efficient access to information and for communication with multiple persons, groups and agencies. ReadyOp is currently being used by numerous federal, state and local government agencies and private enterprises.

Backed by a management team committed to growing its business and finding ways to create value for shareholders, Cleartronic is well-positioned to grow in a broad array of markets. The company has a solid business plan in place that maximizes available resources for accelerated growth and has proven its ability to identify strong business opportunities. Disclaimer

Cleartronic, Inc. Company Blog

Cleartronic, Inc. News:

Cleartronic Announces Expanded License Agreement With Collabria LLC

Cleartronic Appoints Two New Members to Board of Directors

Cleartronic, Inc. (CLRI) Announces Capitalization Benefit Plan and Expansion of Board of Directors

Pure Hospitality Solutions, Inc. (PNOW)

The QualityStocks Daily Newsletter would like to spotlight Pure Hospitality Solutions, Inc. (PNOW). Today, Pure Hospitality Solutions, Inc. closed trading at $0.013, off by 7.14%, on 50,066 volume with 11 trades. The stock’s average daily volume over the past 60 days is 150,024, and its 52-week low/high is $0.0031/$0.8824.

Pure Hospitality Solutions, Inc. announced today, that the Company has made stronger relationships, to ensure that its FROL booking engine is given new life as Oveedia, the anticipated Central-America-Caribbean Online Travel Agency (OTA) to be launched in Costa Rica later this year. "Take a serious look at the OTA market," commented Melvin Pereira, President of Pure Hospitality Solutions, Inc. "One would not ask why, but rather urge us to pay close attention to the revamp of FROL. The reason is simple. Central America and the Latin countries of the Caribbean, currently appear to lack a centralized OTA."

Pure Hospitality Solutions, Inc. (PNOW) is a provider of proprietary technology, marketing solutions, infrastructure and branding services to hotel operators.

The company's innovative platform functions as a powerful vehicle to help hotel operators achieve greater success in three specific areas: (i) expanded international exposure and recognition, (ii) powerful core structure, and (iii) high occupancy rates that drive increases in bottom-line profits. Pure continuously refines its suite of proprietary solutions to deliver measurable and proven results to hotel properties. This success has been reflected in those properties operating under the Hotel PURE brand as well as with independent boutique hotel properties utilizing the company's Friendly Reservation Online (FROL) booking engine technology and internet marketing services.

Operating a successful bi-lateral business model, Pure has four objectives:

1. To franchise the Hotel PURE brand to selected hotel properties worldwide similar to the business model currently employed by Big Brand operators such as Holiday Inn, Marriott, Sheraton and others;

2. Provide highly efficient and economical back-end booking engine technology services to independently branded boutique hotels that require a robust online presence;

3. Launch a stand-alone online hotel booking search engine primarily focused on Central America; and,

4. Expand the portfolio of Pure-owned boutique hotels operating under the Hotel PURE brand.

The company initially began growing its operations primarily in the United States. However most recently, major opportunities in Central America began presenting themselves, giving Oriens the ability to retool its business model. Now the company is positioned to acquire, own and operate its own properties – which would be marketed under the new brand with occupancies handled by the re-launched online booking engine system.

Ultimately, Pure intends to become a top-tier hotel brand operator and Internet booking and marketing service provider, qualifying as a preferred supplier to lending institutions. The company also intends to establish an invaluable international footprint with its online booking engine technology and marketing offerings; making that segment of its business a prime acquisition target for major online travel search and booking engine companies. Advancement toward this goal is guided by an executive management team with deep expertise in technology, banking, management, hospitality, branding and marketing, technical development and more. Disclaimer

Pure Hospitality Solutions, Inc. Company Blog

Pure Hospitality Solutions, Inc. News:

Pure Hospitality Solutions Increases Focus On Partnerships to Develop Oveedia

Pure Expands Oveedia, Aligns With Sabre Travel Network

PURE Hospitality Solutions Launches Non-Toxic Funding Campaign for Oveedia

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.32, up 52.38%, on 5,001 volume with 4 trades. The stock’s average daily volume over the past 60 days is 2,805 and its 52-week low/high is $0.06/$0.60.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview

Dominovas Energy Corp. Appoints International Business Professional to Board of Directors

Dominovas Energy and Delphi Sign MOU

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $8.00, up 15.94%, on 300 volume with 1 trade. The stock’s average daily volume over the past 60 days is 637, and its 52-week low/high is $3.16/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.179, up 12.51%, on 7,716 volume with 6 trades. The stock’s average daily volume over the past 60 days is 37,710, and its 52-week low/high is $0.15/$1.00.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial

Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible

Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device

Mobile Lads Corp. (MOBO)

The QualityStocks Daily Newsletter would like to spotlight Mobile Lads Corp. (MOBO). Today, Mobile Lads Corp. closed trading at $0.13, up 8.33%, on 66,600 volume with 10 trades. The stock’s average daily volume over the past 60 days is 46,309, and its 52-week low/high is $0.091/$0.42.

Mobile Lads Corp. (MOBO) designs and delivers secure, wide-area wireless transaction software solutions for the consumer finance, web and health payment processing sectors. The company’s solutions provide streamlined, continuous access to time-sensitive information and data on multiple network standards. Mobile Lads’ products and services, offered through its Xtreme Mobility division, centers on three core technologies that simplify and secure wireless communications: xmVerify, xmBilling, and xmOne.

xmVerify is a real-time mobile transaction security service that prevents credit card fraud by giving users control over the authorization process when making purchases. Using one of the best cryptographic services, and in compliance with most all available platforms, xmVerify sends a transaction authorization request directly to the user’s mobile phone to ensure authenticity.

xmBilling is a mobile platform that provides customers with a convenient and secure way to review and authorize automatic billing transactions, easing the challenges of automated and volume-based billing. The system sends the user a text message with a URL leading to an online e-bill where they can review details of the bill and authorize the payment via credit card with the use of their PIN number.

The xmOne mobile platform provides an array of encrypted mobile services, including top-up, payment processing, emergency notification and marketing, ideal for students and higher education facilities. xmOne interfaces with a school’s existing campus card account system to enable students to perform a variety of banking transactions from their cell phones. The university or college benefits from increased usage of the flex-dollar ecosystem, reduces overhead from ADMs, and can be customized to each school’s individual brand.

Mobile Lads is guided by a management team with a unique blend of in-depth technical expertise in wireless channel communications and a solid background in business strategy and consumer analysis. The company’s vision is to grow as a leading-edge wireless solution provider by enabling innovative, wide-area communication solutions on a global scale. Disclaimer

Mobile Lads Corp. Company Blog

Mobile Lads Corp. News:

Mobile Lads Purchases Majority of North American Shopping Network From Domark International

Mobile Lads to Launch CouBox, a Next-Generation Mobile Coupon Application

Mobile Lads Acquires Innovative Online Coupon Platform, CouBox

IFAN Financial, Inc. (IFAN)

The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.49, up 4.26%, on 406,626 volume with 128 trades. The stock’s average daily volume over the past 60 days is 714,598, and its 52-week low/high is $0.0114/$1.01.

IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.

Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.

Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.

IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer

IFAN Financial, Inc. Company Blog

IFAN Financial, Inc. News:

IFAN Financial, Inc. Announces Stock-Based Compensation Plan

IFAN Financial, Inc. Announces the Launch of New Website and Investor Relations Kit

IFAN Financial Enters Agreement to Provide Development Assistance to Card Collaborative International, LLC

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

TaglichBrothers
(CLRX)

2.

QualityStocks
(DNRG)

3.

BUYINS.NET
(BIOC)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251